PetMed Express Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van PetMed Express zullen naar verwachting dalen met respectievelijk 4.6% en 51.2% per jaar. De winst per aandeel zal naar verwachting afnemen met 50.2% per jaar. Het rendement op het eigen vermogen zal naar verwachting 1.2% in 3 jaar.

Belangrijke informatie

-51.2%

Groei van de winst

-50.2%

Groei van de winst per aandeel

Specialty Retail winstgroei	9.3%
Inkomstengroei	-4.6%
Toekomstig rendement op eigen vermogen	1.2%
Dekking van analisten	Low
Laatst bijgewerkt	17 Apr 2025

Recente toekomstige groei-updates

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 09

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Jun 14

Recent updates

Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%

Apr 09

Cost Cuts And Digital Upgrades Will Strain Future Margins

Apr 06 Optimism regarding savings from PetCareRx integration could jeopardize future profitability if anticipated savings do not materialize.

PetMed Express: Dip Or Rip, A Buy After Earnings

Feb 10

We Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth

Feb 08

Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding

Jan 09

PetMed Express: Why (And Why Not) The Rebound Could Continue

Nov 12

Optimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking

Oct 04

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 09

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Jun 14

PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price

Jun 12

PetMed Express CFO to leave post today, by remain with company over transition period

Aug 02

PetMed Express' (NASDAQ:PETS) Dividend Will Be $0.30

Jul 29

PetMed Express FQ1 2023 Earnings Preview

Jul 24

Winst- en omzetgroeiprognoses

NasdaqGS:PETS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	220	1	N/A	N/A	1
3/31/2026	227	-2	N/A	N/A	2
3/31/2025	232	4	N/A	N/A	2
12/31/2024	247	0	1	5	N/A
9/30/2024	259	-1	-1	3	N/A
6/30/2024	271	-3	-9	-5	N/A
3/31/2024	281	-7	0	4	N/A
12/31/2023	277	-3	2	7	N/A
9/30/2023	270	-1	17	22	N/A
6/30/2023	265	1	17	22	N/A
3/31/2023	257	5	23	28	N/A
12/31/2022	259	9	23	27	N/A
9/30/2022	261	13	19	23	N/A
6/30/2022	263	17	23	25	N/A
3/31/2022	272	19	17	18	N/A
12/31/2021	279	22	26	28	N/A
9/30/2021	284	25	24	26	N/A
6/30/2021	292	27	48	51	N/A
3/31/2021	304	24	38	40	N/A
12/31/2020	312	31	37	39	N/A
9/30/2020	306	30	34	37	N/A
6/30/2020	300	28	25	28	N/A
3/31/2020	284	26	37	39	N/A
12/31/2019	274	25	33	35	N/A
9/30/2019	275	26	41	42	N/A
6/30/2019	276	31	23	23	N/A
3/31/2019	283	38	45	45	N/A
12/31/2018	286	41	34	34	N/A
9/30/2018	286	43	N/A	39	N/A
6/30/2018	282	41	N/A	46	N/A
3/31/2018	274	37	N/A	37	N/A
12/31/2017	270	35	N/A	51	N/A
9/30/2017	262	30	N/A	38	N/A
6/30/2017	256	27	N/A	48	N/A
3/31/2017	249	24	N/A	47	N/A
12/31/2016	242	22	N/A	30	N/A
9/30/2016	240	22	N/A	35	N/A
6/30/2016	236	21	N/A	23	N/A
3/31/2016	235	21	N/A	21	N/A
12/31/2015	229	20	N/A	25	N/A
9/30/2015	228	20	N/A	22	N/A
6/30/2015	228	18	N/A	29	N/A
3/31/2015	229	17	N/A	32	N/A
12/31/2014	228	17	N/A	25	N/A
9/30/2014	229	17	N/A	13	N/A
6/30/2014	232	18	N/A	8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van PETS zal naar verwachting de komende 3 jaar dalen ( -51.2% per jaar).

Winst versus markt: De winst van PETS zal naar verwachting de komende 3 jaar dalen ( -51.2% per jaar).

Hoge groeiwinsten: De winst van PETS zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van PETS zal naar verwachting de komende 3 jaar dalen ( -4.6% per jaar).

Hoge groei-inkomsten: De omzet van PETS zal naar verwachting de komende 3 jaar dalen ( -4.6% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen PETS zal naar verwachting over 3 jaar laag zijn ( 1.2 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/04/17 00:21
Aandelenkoers aan het einde van de dag	2025/04/17 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

PetMed Express, Inc. wordt gevolgd door 18 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Erin Wilson Wright	BofA Global Research
Kristine Koerber	Citizens JMP Securities, LLC
David Westenberg	CL King & Associates, Inc.

PetMed Express Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased by 21% to US$7.75

Price target decreased by 18% to US$15.00

Consensus EPS estimates fall by 31%, revenue upgraded

Consensus EPS estimates fall by 20%

Recent updates

PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors, Effective April 09, 2025

Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%

Cost Cuts And Digital Upgrades Will Strain Future Margins

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

PetMed Express: Dip Or Rip, A Buy After Earnings

We Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth

PetMed Express, Inc. to Report Q3, 2025 Results on Feb 10, 2025

Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding

Independent Chairman of the Board recently bought US$325k worth of stock

PetMed Express: Why (And Why Not) The Rebound Could Continue

New minor risk - Share price stability

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

PetMed Express, Inc. to Report Q2, 2025 Results on Nov 06, 2024

Optimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking

PetMed Express, Inc. Appoints Robyn DElia as Chief Financial Officer, Effective September 16, 2024

New major risk - Revenue and earnings growth

PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

New minor risk - Share price stability

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Petmed Express, Inc. Appoints Doug Krulik as Chief Accounting Officer, Effective August 19, 2024

PetMed Express, Inc. to Report Q1, 2025 Results on Aug 06, 2024

PetMed Express, Inc.(NasdaqGS:PETS) dropped from Russell 3000 Index

PetMed Express, Inc., Annual General Meeting, Aug 08, 2024

PetMed Express, Inc. Announces Appointment of Leah Solivan to Board of Directors

PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates

Full year 2024 earnings: EPS misses analyst expectations

New major risk - Revenue and earnings growth

PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price

PetMed Express, Inc. Announces Christine Chambers Will Leave the Company in Early August 2024

PetMed Express, Inc. Appoints Carla Dodds as Chief Marketing Officer

PetMed Express, Inc. to Report Q4, 2024 Results on Jun 11, 2024

PetMed Express, Inc. Appoints Justin Mennen to Board of Directors, Effective June 3, 2024

Price target decreased by 21% to US$7.75

PetMed Express, Inc. Announces Executive Changes

PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. announced delayed 10-Q filing

PetMed Express, Inc. to Report Q3, 2024 Results on Feb 08, 2024

PetMed Express, Inc. Announces Management Changes

Independent Chairman of the Board recently bought US$301k worth of stock

CEO, President & Director recently bought US$101k worth of stock

PetMed Express, Inc. Makes Decision to Suspend the Quarterly Dividend Effective the Quarter Ended September 30, 2023

PetMed Express, Inc. to Report Q2, 2024 Results on Oct 30, 2023

Price target decreased by 18% to US$15.00

Now 21% undervalued after recent price drop

A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)

PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30

Upcoming dividend of US$0.30 per share at 9.0% yield

First quarter 2024 earnings: EPS and revenues miss analyst expectations

PetMed Express, Inc. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

High number of new directors

Consensus EPS estimates fall by 31%, revenue upgraded

Upcoming dividend of US$0.30 per share at 8.1% yield

Full year 2023 earnings: EPS and revenues miss analyst expectations

PetMed Express, Inc. Declares a Quarterly Dividend, Payable on June 12, 2023

PetMed Express, Inc., Annual General Meeting, Aug 03, 2023

Now 22% undervalued after recent price drop

PetMed Express, Inc. Appoints Sandra Y. Campos to its Board of Directors

PetMed Express, Inc. to Report Q4, 2023 Results on May 22, 2023

Consensus EPS estimates fall by 20%

The Returns On Capital At PetMed Express (NASDAQ:PETS) Don't Inspire Confidence

Consensus EPS estimates fall by 48%

PetMed Express (NASDAQ:PETS) Will Pay A Dividend Of $0.30

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.21 profit in 3Q 2022)

PetMed Express, Inc. Declares Quarterly Dividend, Payable on February 27, 2023

Investor sentiment improves as stock rises 16%

PetMed Express, Inc. to Report Q3, 2023 Results on Feb 06, 2023

PetMed Express, Inc. entered into an agreement to acquire PetCareRx, Inc. from Evolution VC Partners and Feenix Venture Partners.